Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE1A | P54750 | 7/20 | 0.50 |
| ▸ | PDE1B | Q01064 | 7/20 | 0.50 |
| ▸ | PDE1C | Q14123 | 7/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | LSS | P48449 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21114008 | 0.94 | KDM4E (0.55) | PDE1APDE1BPDE1CKDM4ESMN1; SMN2 | |
| SCHEMBL19553110 | 0.82 | KDM4E (0.56) | KDM4ESMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL27164572 | 0.81 | SMN1; SMN2 (0.53) | KDM4ESMN1; SMN2ALDH1A1LTA4HHRH3 | |
| SCHEMBL17572343 | 0.81 | PDK2 (0.47) | PDE1APDE1BPDE1CKDM4ESMN1; SMN2 | |
| SCHEMBL10877728 | 0.80 | LTA4H (0.69) | KDM4ESMN1; SMN2ALDH1A1LTA4H | |
| SCHEMBL5637895 | 0.79 | KDM4E (0.69) | PDE1APDE1BPDE1CKDM4ESMN1; SMN2 | |
| SCHEMBL2476605 | 0.77 | KDM4E (0.49) | KDM4ESMN1; SMN2ALDH1A1LTA4HMEN1 | |
| SCHEMBL21595690 | 0.77 | DRD2 (0.60) | KDM4ESMN1; SMN2MEN1KMT2A | |
| SCHEMBL7994823 | 0.76 | LTA4H (0.56) | KDM4ESMN1; SMN2ALDH1A1LTA4HMEN1 | |
| SCHEMBL21163143 | 0.76 | PDK2 (0.45) | PDE1APDE1BPDE1CKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3190111-B1 | PYRAZOLO[3,4-C]PYRIDINE DERIVATIVES | CSPC ZHONGQI PHARMACEUTICAL TECH SHIJIAZHUANG CO LTD (CN) | 2020-05-06 | — | — | EP | disclosed |
| US-9975893-B2 | Pyrazolo[3,4-c]pyridine derivatives | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2018-05-22 | — | — | US | disclosed |
| US-20170291896-A1 | PYRAZOLO[3,4-C]PYRIDINE DERIVATIVES | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2017-10-12 | — | — | US | disclosed |
| EP-3190111-A1 | PYRAZOLO[3,4-C]PYRIDINE DERIVATIVES | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) | 2017-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170291896-A1 | PYRAZOLO[3,4-C]PYRIDINE DERIVATIVES | F11, TFPI, F2 | PDE1A 529/4885PDE1B 705/4885PDE1C 872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.